leisure time -WSS

leisure time

author：explore 2025-10-01 02:42:36 - browse：783

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Hyaluronic acid injections don’t help knee osteoarthritis, study finds

WSS

STAT Summit: Biotech founders on deal

FDA warns J&J's Abiomed: We will regulate your software

STAT Readout Newsletter: Today's biggest biotech updates

The EU Joint Clinical Assessment needs to live up to its promise

Providers still hesitate to prescribe buprenorphine, study finds

Marvel Studios reveals new trailer for 'The Marvels': Watch here

entertainment

leisure time

Gilead needs Arcellx more than ever

knowledge

Medicare details structure of new drug price negotiation program

Caitlin Bernard's story shows physicians can't shy from advocacy

Moonlake's readout produced a cash windfall. Risks remain

STAT Summit: Michael J. Fox on progress in Parkinson's research

Sports medicine is finally prioritizing gender equality

CDC backtracks, saying fully vaccinated people can go maskless indoors

What does generative AI mean for health care? We asked experts

STAT Readout Newsletter: Today's biggest biotech updates

Medicare proposal to cover medical devices draws a mixed reaction

Will.i.am, Britney Spears release new single, 'Mind Your Business'

focus

How climate

HIPAA doesn't protect reproductive records from prosecutors

Will Ozempic

A double vaccine crisis is endangering millions of children

FDA struggles to regulate food additives, sometimes for decades

FDA official pushes for dedicated emerging pathogens team

leisure time

hotspot

focus

explore